Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

NetraMark Holdings Inc C.AIAI

Alternate Symbol(s):  AINMF

Technology Software - Application
NetraMark Holdings Inc. is a Canada-based company, which is focused on the development of Generative Artificial Intelligence (Gen AI)/Machine Learning (ML) solutions targeted at the pharmaceutical industry. The Company’s product offering uses a novel topology-based algorithm that has the ability to parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows the Company to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent data that activates traditional AI/ML methods. The result is that it can work with smaller datasets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment. The typical molecular data used is RNASeq, microarray, single nucleotide polymorphism (SNP) and methylation.


CSE:AIAI - Post by User

NetraMark Holdings Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(1)
•••
Post by SkywalkerofLukeon Nov 05, 2021 3:48pm
118 Views
Post# 34093893

Interview with $MEND CEO

Interview with $MEND CEO

Found this recent interview with the CEO of $MEND $MEND.c along with one of their celebrity advisors, professional hockey player James Van Riemsdyk.


Discusses 


- Nuro app and what makes it unique

- Plans for the future

- Van Riemsdyk’s belief in the app and its tech

- How $MEND looks to address a gap in the mental health sector

- Etc. 


MEND chart clearly showing a falling wedge here. RSI trending higher and >50 - very positive MACD. Looking primed to break out any time. Will be keeping an eye here. 


https://cheddar.com/media/nuro-app-digitizes-experience-of-seeing-a-neurologist?mc_cid=8e9d5aa6cc&mc_eid=UNIQID

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities